We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Translating the Human Genome Project Into Prevention of Myocardial Infarction and Stroke—Getting Close?

Christopher J. O’Donnell, MD, MPH
JAMA. 2005;293(18):2277-2279. doi:10.1001/jama.293.18.2277.
Text Size: A A A
Published online


With a nearly completed Human Genome Project,1 it is hoped that the road from the complete genome sequence of 2.85 billion nucleotides containing up to 25 000 genes will lead to a promised land of new and better patient-tailored diagnostics and treatments. Some have even predicted the end of common complex diseases such as myocardial infarction (MI) as a major public health problem in the near future.2 Risks for MI and stroke are conferred by established major modifiable risk factors, including hyperlipidemia and hypertension, as well as other factors, such as inflammation. Cardiovascular disease risks are also substantially increased in those with disease occurrence in twin siblings3 or parents.4 This suggests that genetic variation may lead to increased risk, although to date few genetic variants have emerged as strong candidates. The randomized trial described by Hakonarson et al5 in this issue of JAMA—suggesting that inhibition of a genetically encoded 5-lipoxygenase–activating protein (FLAP) in patients with at-risk genotypes may reduce biomarkers of cardiovascular risk—illustrates the exciting potential opportunity for rapidly translating genomics into novel diagnostics and treatments.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

6 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Evidence To Support The Update

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference